Literature DB >> 23993387

Aurora kinases in head and neck cancer.

Ranee Mehra1, Ilya G Serebriiskii, Barbara Burtness, Igor Astsaturov, Erica A Golemis.   

Abstract

In healthy cells, controlled activation of aurora kinases regulates mitosis. Overexpression and hyperactivation of aurora kinases A and B have major roles in tumorigenesis, and can induce aneuploidy and genomic instability. In squamous-cell carcinomas of the head and neck, overexpression of aurora kinase A is associated with decreased survival, and a reduction in aurora kinase A and aurora kinase B expression inhibits cell growth and increases apoptosis. In this Review, we provide an overview of the biological functions of aurora kinases in healthy cells and in cancer cells, and we review small studies and high-throughput datasets that particularly implicate aurora kinase A in the pathogenesis of squamous-cell carcinomas of the head and neck. Early phase trials are beginning to assess the activity of small-molecule inhibitors of aurora kinases. We summarise trials of aurora kinase inhibitors in squamous-cell carcinomas of the head and neck, and discuss directions for future drug combination trials and biomarkers to use with drugs that inhibit aurora kinases.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23993387      PMCID: PMC4139969          DOI: 10.1016/S1470-2045(13)70128-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  88 in total

1.  Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.

Authors:  Daruka Mahadevan; Amy Stejskal; Laurence S Cooke; Ann Manziello; Carla Morales; Daniel O Persky; Richard I Fisher; Thomas P Miller; Wenqing Qi
Journal:  Clin Cancer Res       Date:  2012-02-28       Impact factor: 12.531

Review 2.  Cancer treatment and survivorship statistics, 2012.

Authors:  Rebecca Siegel; Carol DeSantis; Katherine Virgo; Kevin Stein; Angela Mariotto; Tenbroeck Smith; Dexter Cooper; Ted Gansler; Catherine Lerro; Stacey Fedewa; Chunchieh Lin; Corinne Leach; Rachel Spillers Cannady; Hyunsoon Cho; Steve Scoppa; Mark Hachey; Rebecca Kirch; Ahmedin Jemal; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2012-06-14       Impact factor: 508.702

3.  Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.

Authors:  Arijit Chakravarty; Vaishali Shinde; Josep Tabernero; Andres Cervantes; Roger B Cohen; E Claire Dees; Howard Burris; Jeffrey R Infante; Teresa Macarulla; Elena Elez; Jordi Andreu; Edith Rodriguez-Braun; Susana Rosello; Margaret von Mehren; Neal J Meropol; Corey J Langer; Bert ONeil; Douglas Bowman; Mengkun Zhang; Hadi Danaee; Laura Faron-Yowe; Gary Gray; Hua Liu; Jodi Pappas; Lee Silverman; Chris Simpson; Bradley Stringer; Stephen Tirrell; Ole Petter Veiby; Karthik Venkatakrishnan; Katherine Galvin; Mark Manfredi; Jeffrey A Ecsedy
Journal:  Cancer Res       Date:  2010-12-10       Impact factor: 12.701

4.  Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation.

Authors:  Margaret A Bolton; Weijie Lan; Shannon E Powers; Mark L McCleland; Jian Kuang; P Todd Stukenberg
Journal:  Mol Biol Cell       Date:  2002-09       Impact factor: 4.138

5.  Aurora kinase A inhibition and paclitaxel as targeted combination therapy for head and neck squamous cell carcinoma.

Authors:  Abhijit Mazumdar; Ying C Henderson; Adel K El-Naggar; Subrata Sen; Gary L Clayman
Journal:  Head Neck       Date:  2009-05       Impact factor: 3.147

Review 6.  Aurora A kinase (AURKA) in normal and pathological cell division.

Authors:  Anna S Nikonova; Igor Astsaturov; Ilya G Serebriiskii; Roland L Dunbrack; Erica A Golemis
Journal:  Cell Mol Life Sci       Date:  2012-08-03       Impact factor: 9.261

Review 7.  HEF1-aurora A interactions: points of dialog between the cell cycle and cell attachment signaling networks.

Authors:  Elena N Pugacheva; Erica A Golemis
Journal:  Cell Cycle       Date:  2006-02-15       Impact factor: 4.534

8.  Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha.

Authors:  Paraskevi Briassouli; Florence Chan; Kay Savage; Jorge S Reis-Filho; Spiros Linardopoulos
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

9.  Overexpression of Aurora-A promotes laryngeal cancer progression by enhancing invasive ability and chromosomal instability.

Authors:  Hao Zhang; Xuehua Chen; Yuesheng Jin; Bingya Liu; Liang Zhou
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-17       Impact factor: 2.503

10.  Constitutive phosphorylation of aurora-a on ser51 induces its stabilization and consequent overexpression in cancer.

Authors:  Shojiro Kitajima; Yasusei Kudo; Ikuko Ogawa; Masaaki Tatsuka; Hidehiko Kawai; Michele Pagano; Takashi Takata
Journal:  PLoS One       Date:  2007-09-26       Impact factor: 3.240

View more
  32 in total

1.  Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.

Authors:  Beverly A Teicher; Eric Polley; Mark Kunkel; David Evans; Thomas Silvers; Rene Delosh; Julie Laudeman; Chad Ogle; Russell Reinhart; Michael Selby; John Connelly; Erik Harris; Anne Monks; Joel Morris
Journal:  Mol Cancer Ther       Date:  2015-09-08       Impact factor: 6.261

2.  Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.

Authors:  Myriem Boufraqech; Dhaval Patel; Naris Nilubol; Astin Powers; Timothy King; Jasmine Shell; Justin Lack; Lisa Zhang; Sudheer Kumar Gara; Viswanath Gunda; Joanna Klubo-Gwiezdzinska; Suresh Kumar; James Fagin; Jeffrey Knauf; Sareh Parangi; David Venzon; Martha Quezado; Electron Kebebew
Journal:  Thyroid       Date:  2018-12-28       Impact factor: 6.568

3.  Knockdown of Aurora-B alters osteosarcoma cell malignant phenotype via decreasing phosphorylation of VCP and NF-κB signaling.

Authors:  Jian Ying He; Wei Hong Xi; Liang Bo Zhu; Xin Hua Long; Xuan Yin Chen; Jia Min Liu; Qin Feng Luo; Xiao Ping Zhu; Zhi Li Liu
Journal:  Tumour Biol       Date:  2015-01-21

Review 4.  Kinase signaling and targeted therapy for primary myelofibrosis.

Authors:  Qiong Yang; John D Crispino; Qiang Jeremy Wen
Journal:  Exp Hematol       Date:  2016-12-30       Impact factor: 3.084

5.  In vitro evaluation of a combination treatment involving anticancer agents and an aurora kinase B inhibitor.

Authors:  Senna Sakai; Hiroto Izumi; Yukiko Yoshiura; Yoshifumi Nakayama; Takahiro Yamaguchi; Yoshikazu Harada; Chiho Koi; Hiroyuki Kurata; Yasuo Morimoto
Journal:  Oncol Lett       Date:  2016-09-20       Impact factor: 2.967

6.  C-X-C motif receptor 7 in gastrointestinal cancer.

Authors:  Hwan-Jung Yun; Hyewon Ryu; Yoon Seok Choi; Ik-Chan Song; Deog-Yeon Jo; Samyong Kim; Hyo Jin Lee
Journal:  Oncol Lett       Date:  2015-06-22       Impact factor: 2.967

7.  Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.

Authors:  Jong Woo Lee; Janaki Parameswaran; Teresa Sandoval-Schaefer; Kyung Jin Eoh; Dong-Hua Yang; Fang Zhu; Ranee Mehra; Roshan Sharma; Stephen G Gaffney; Elizabeth B Perry; Jeffrey P Townsend; Ilya G Serebriiskii; Erica A Golemis; Natalia Issaeva; Wendell G Yarbrough; Ja Seok Koo; Barbara Burtness
Journal:  Clin Cancer Res       Date:  2019-02-12       Impact factor: 12.531

8.  Expression of Aurora-B and FOXM1 predict poor survival in patients with nasopharyngeal carcinoma.

Authors:  Pei-Yu Huang; Yan Li; Dong-Hua Luo; Xue Hou; Ting-Ting Zeng; Meng-Qing Li; Hai-Qiang Mai; Li Zhang
Journal:  Strahlenther Onkol       Date:  2015-05-19       Impact factor: 3.621

9.  Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells.

Authors:  Muhammad Furqan; Zille Huma; Zainab Ashfaq; Apsra Nasir; Rahim Ullah; Aishah Bilal; Maheen Iqbal; Muhammad Hashaam Khalid; Irshad Hussain; Amir Faisal
Journal:  Cell Cycle       Date:  2019-07-26       Impact factor: 4.534

Review 10.  Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.

Authors:  Shanthi Marur; Barbara Burtness
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.